What are the risks of brain metastasis in patients diagnosed with lung cancer?

Brain metastases are a serious complication of lung cancer, occurring when cancer cells spread from the lungs to the brain. The risk varies by lung cancer type and individual factors. For small cell lung cancer (SCLC), about 15% of patients already have brain metastases at the time of diagnosis ⁹. For non-small cell lung cancer (NSCLC), the risk is also significant, and certain blood markers may help identify those at higher risk ⁸. Fortunately, newer treatments like targeted therapies and stereotactic radiosurgery can effectively manage brain metastases in many patients ⁷¹⁰.

What the research says

The risk of brain metastasis differs by lung cancer subtype. In small cell lung cancer (SCLC), approximately 15% of patients have brain metastases at diagnosis, and the 5-year survival rate ranges from 12% to 30% ⁹. For non-small cell lung cancer (NSCLC), brain metastases are also common and significantly worsen prognosis ¹¹. A 2025 meta-analysis of 14 studies found that an elevated neutrophil-to-lymphocyte ratio (NLR) in the blood is an independent risk factor for developing brain metastases from lung cancer, with an odds ratio of 1.61 ⁸. This means patients with higher NLR are about 1.6 times more likely to develop brain metastases.

Once brain metastases occur, treatment options have improved. For patients with EGFR-mutated NSCLC, the targeted therapy osimertinib showed an intracranial objective response rate of 81.8% in patients with measurable brain metastases, meaning the tumors shrank significantly in most patients ⁷. Stereotactic radiosurgery (SRS) is a precise radiation technique that offers high local control and preserves cognitive function, and it is recommended for patients with 1 to 4 brain metastases from solid tumors, excluding SCLC ¹⁰. For SCLC, whole-brain radiotherapy may be used, but outcomes remain poor, with median survival often measured in months ²⁹.

The tumor microenvironment also plays a role. Research shows that brain metastases from lung cancer involve complex interactions between tumor cells and the brain's immune system, including disruption of the blood-brain barrier and formation of an immunosuppressive niche ⁵. Understanding these mechanisms may lead to new therapies. Additionally, combining radiomic features from MRI scans with genetic data can help predict survival in NSCLC patients with brain metastases, potentially guiding personalized treatment ¹¹.

What to ask your doctor

• What is my personal risk of developing brain metastases based on my lung cancer type and stage?
• Should I have routine brain imaging (like MRI) to check for brain metastases, even if I have no symptoms?
• If I have an EGFR mutation, is osimertinib a good option for treating or preventing brain metastases?
• What are the benefits and risks of stereotactic radiosurgery versus whole-brain radiotherapy for my situation?
• Could my neutrophil-to-lymphocyte ratio (NLR) be used to help assess my risk of brain metastases?